Exclusive Summary

• First-in-Class (FIC) Mechanism: UB675 is a worldly innovative CD80/PD-1 fusion protein globally that simultaneously engages four targets (PD-L1/PD-L2 and CD28/CTLA-4), smartly combining immune checkpoint inhibition with costimulation.
• Directly Addresses PD-1 Resistance & "Cold Tumors": Preclinical studies reveal its efficacy is independent of tumor PD-L1 expression levels, successfully overcoming primary and adaptive immune resistance while turning "cold tumors" hot.
• Optimal Balance of Efficacy and Safety: Engineered for precise, local activation within the Tumor Microenvironment (TME), it promotes mild T-cell activation to exert potent anti-tumor mechanisms (including establishing immune memory to prevent recurrence) with minimized systemic toxicity risks.
• High Value for Global Licensing & Partnering: Backed by robust global patent protection and unencumbered global rights, it targets the massive $55 billion IO market, positioning itself as an ideal out-licensing or co-development asset for global pharma companies seeking next-generation immunotherapies.

Asset Materials

Contact Us for Full Materials